SOPHiA GENETICS (SOPH) Stock Price
SOPHiA GENETICS Price
Over the last 6 years SOPHiA GENETICS grew revenue by 20.0% annually, reaching 72.72 M USD. For SOPHiA GENETICS, the net margin of -108.6% is up versus -185.2% a few years ago. The consensus 12-month price target for SOPHiA GENETICS is 11.50 USD, about 39.2% above where the stock trades today. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus. The stock trades about 141% above its 52-week low.
SOPHiA GENETICS stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of SOPHiA GENETICS over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how SOPHiA GENETICS stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing SOPHiA GENETICS's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | SOPHiA GENETICS Price |
|---|---|
| 9/24/2026 | 8.26 USD |
| 9/22/2026 | 8.27 USD |
| 9/21/2026 | 8.19 USD |
| 9/18/2026 | 8.21 USD |
| 9/17/2026 | 8.53 USD |
| 9/16/2026 | 8.01 USD |
| 9/15/2026 | 7.90 USD |
| 9/14/2026 | 7.86 USD |
| 9/13/2026 | 7.92 USD |
| 9/11/2026 | 7.63 USD |
| 9/10/2026 | 7.61 USD |
| 9/9/2026 | 7.68 USD |
| 9/8/2026 | 8.05 USD |
| 9/4/2026 | 8.09 USD |
| 9/3/2026 | 8.30 USD |
| 9/2/2026 | 8.28 USD |
| 9/1/2026 | 8.43 USD |
| 8/31/2026 | 8.40 USD |
| 8/30/2026 | 8.30 USD |
| 8/28/2026 | 8.08 USD |
| 8/27/2026 | 8.72 USD |
| 8/26/2026 | 8.53 USD |
| 8/25/2026 | 8.65 USD |
| 8/24/2026 | 8.51 USD |
| 8/21/2026 | 8.65 USD |
| 8/20/2026 | 8.33 USD |
| 8/19/2026 | 7.86 USD |
| 8/18/2026 | 7.66 USD |
| 8/14/2026 | 7.50 USD |
| 8/13/2026 | 7.62 USD |
SOPHiA GENETICS Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
SOPHiA GENETICS Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 25.00 | 28.00 | 40.00 | 47.00 | 62.00 | 65.00 | 77.00 | 95.00 | 117.00 | 150.00 | 193.00 | 259.00 |
| – | 12.00 | 42.86 | 17.50 | 31.91 | 4.84 | 18.46 | 23.38 | 23.16 | 28.21 | 28.67 | 34.20 |
| 68.00 | 60.71 | 62.50 | 65.96 | 67.74 | 66.15 | 61.04 | 61.04 | 61.04 | 61.04 | 61.04 | 61.04 |
| 17.00 | 17.00 | 25.00 | 31.00 | 42.00 | 43.00 | 47.00 | 57.99 | 71.42 | 91.56 | 117.81 | 158.09 |
| -32.00 | -40.00 | -72.00 | -87.00 | -74.00 | -66.00 | -75.00 | -62.00 | -40.00 | -30.00 | 3.00 | 47.00 |
| -128.00 | -142.86 | -180.00 | -185.11 | -119.35 | -101.54 | -97.40 | -65.26 | -34.19 | -20.00 | 1.55 | 18.15 |
| -33.00 | -39.00 | -73.00 | -87.00 | -78.00 | -62.00 | -78.00 | -63.00 | -42.00 | -24.00 | – | 35.00 |
| – | 18.18 | 87.18 | 19.18 | -10.34 | -20.51 | 25.81 | -19.23 | -33.33 | -42.86 | – | – |
| 38.00 | 48.02 | 59.60 | 64.22 | 65.03 | 65.90 | 68.24 | 68.24 | 68.24 | 68.24 | 68.24 | 68.24 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales SOPHiA GENETICS generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue SOPHiA GENETICS retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare SOPHiA GENETICS's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares SOPHiA GENETICS has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against SOPHiA GENETICS's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
SOPHiA GENETICS stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
SOPHiA GENETICS Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
SOPHiA GENETICS business model & stock analysis
SOPHiA GENETICS SWOT Analysis
Strengths
Sophia Genetics SA has several strengths that contribute to its success:
- Advanced technology platform for genetic data analysis and interpretation
- Wide range of genetic tests offered, covering various diseases and conditions
- Strong network of partnerships with hospitals, laboratories, and research institutions
- Well-established brand reputation in the genetic testing industry
- Experienced and highly skilled team of geneticists and bioinformaticians
Weaknesses
Some weaknesses that Sophia Genetics SA needs to address:
- Relatively high costs associated with genetic testing services
- Limited market reach and presence in certain geographic regions
- Dependence on external partners for sample collection and processing
- Risk of potential data breaches or privacy concerns due to sensitive genetic information
- Competition from other genetic testing companies and emerging technologies
Opportunities
There are several opportunities for Sophia Genetics SA to capitalize on:
- Increasing demand for personalized medicine and precision healthcare
- Growing adoption of genetic testing in research and clinical settings
- Potential for expansion into untapped markets and collaborations with new partners
- Advancements in genomic technologies, creating opportunities for innovation
- Strategic acquisitions or alliances to enhance product offerings and market presence
Threats
Sophia Genetics SA faces several threats that may impact its growth:
- Regulatory challenges and evolving legal frameworks for genetic testing
- Emergence of competitors offering similar or alternative genetic testing solutions
- Rapidly changing technologies and potential obsolescence of existing platforms
- Public concerns over privacy and ethical implications of genetic testing
- Economic downturn and reduced healthcare spending affecting market demand
SOPHiA GENETICS Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
SOPHiA GENETICS Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
SOPHiA GENETICS historical P/E ratio, EBIT multiple, and P/S ratio
SOPHiA GENETICS annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down SOPHiA GENETICS's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in SOPHiA GENETICS's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare SOPHiA GENETICS's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
SOPHiA GENETICS shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current SOPHiA GENETICS forecasts and price targets in September 2026
Analyst Price Targets 2026SOPHiA GENETICS Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/5/2026 | Maintained | Buy | – | |
| 8/5/2026 | Maintained | Buy | 49 | |
| 6/15/2026 | Maintained | Buy | 49 | |
| 5/6/2026 | Maintained | Buy | 49 | |
| 4/15/2026 | Maintained | Buy | 49 | |
| 1/26/2026 | Maintained | Buy | 39 | |
| 11/10/2025 | Maintained | Buy | 49 | |
| 8/7/2024 | Maintained | Outperform | 48 | |
| 3/6/2024 | Maintained | Outperform | 48 | |
| 3/6/2024 | Maintained | Buy | 49 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
SOPHiA GENETICS Earnings Calls
SOPHiA GENETICS Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/3/2026 | -0.20USD | - | 24.03 MUSD | - | 2026 Q3 |
| 8/4/2026 | -0.21USD | -0.26USD | 21.72 MUSD | - | 2026 Q2 |
| 5/5/2026 | -0.23USD | -0.27USD | 20.40 MUSD | - | 2026 Q1 |
| 3/3/2026 | -0.24USD | -0.28USD | 20.49 MUSD | - | 2025 Q4 |
| 11/4/2025 | -0.20USD | -0.30USD | 20.49 MUSD | - | 2025 Q3 |
| 8/5/2025 | -0.21USD | 0.33USD | 18.36 MUSD | - | 2025 Q2 |
| 5/6/2025 | -0.21USD | -0.26USD | 17.44 MUSD | - | 2025 Q1 |
| 3/4/2025 | -0.23USD | -0.23USD | 16.99 MUSD | - | 2024 Q4 |
| 11/5/2024 | -0.24USD | -0.28USD | 18.08 MUSD | - | 2024 Q3 |
| 8/6/2024 | -0.28USD | -0.23USD | 17.40 MUSD | - | 2024 Q2 |
SOPHiA GENETICS shareholder structure
| % | Name |
|---|---|
10.00672% | |
5.82785% | |
5.48141% | |
4.98414% | |
3.48453% | |
3.26714% |
SOPHiA GENETICS Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
10.60% | SEC ↗ | |
10.60% | SEC ↗ | |
10.60% | SEC ↗ | |
10.60% | SEC ↗ | |
5.60% | SEC ↗ | |
5.30% | SEC ↗ | |
5.00% | SEC ↗ | |
4.97% | SEC ↗ |
SOPHiA GENETICS Executives and Management Board
13 members · avg. age 54 · 15 % women
Management
Mr. Ross Muken (45)
President
Dr. Jurgi Camblong (46)
Chief Executive Officer, Co-Founder, Director · since 2011
Mr. George Cardoza (63)
Chief Financial Officer
Ms. Manuela Da Silva Valente (55)
Chief People Officer
Dr. Zhenyu Xu (42)
Chief Scientific Officer
Mr. Daan Van Well (50)
Chief Legal and Compliance Officer
Board of Directors
Mr. Troy Cox (60)
Non-Executive Independent Chairman of the Board
Dr. Tomer Berkovitz (45)
Non-Executive Independent Director
Mr. Jean-Michel Cossiery (65)
Non-Executive Independent Director
Ms. Kathy Hibbs (61)
Non-Executive Independent Director
Mr. Didier Hirsch (73)
Non-Executive Independent Director
Dr. Vincent Ossipow (56)
Non-Executive Independent Director
SOPHiA GENETICS Supply Chain
SOPHiA GENETICS Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.65 | — | — | ||
| 2 | 0.43 | — | — | ||
| 3 | 0.86 | — | — | ||
| 4 | PerkinElmer | 0.83 | — | — | |
| 5 | 0.69 | — | — |
Frequently asked questions about SOPHiA GENETICS
The business model of Sophia Genetics SA is focused on providing advanced data analytics solutions for genomic testing. Sophia Genetics offers a cloud-based platform that utilizes artificial intelligence (AI) and machine learning algorithms to analyze genetic data and assist healthcare professionals in making more accurate diagnoses and treatment decisions. They collaborate with a wide network of medical laboratories worldwide, helping to improve the accessibility and efficiency of genomic testing. With their comprehensive suite of solutions, Sophia Genetics aims to drive precision medicine and enable personalized healthcare on a global scale.
Sophia Genetics SA is primarily active in the healthcare and biotechnology industries.
The main competitors of Sophia Genetics SA in the market include companies such as Illumina, Thermo Fisher Scientific, and Qiagen.
Sophia Genetics SA is a leading healthtech company specializing in data-driven medicine and advanced genomic analysis. Founded in 2011 by Jurgi Camblong and Pierre Hutter, the company has since revolutionized the field of clinical genomics. Sophia Genetics uses artificial intelligence and machine learning to analyze patients' genomic data, providing accurate diagnoses and personalized treatment recommendations. With offices in Switzerland, the United States, and other countries, Sophia Genetics has collaborated with over 1,000 hospitals worldwide, improving patient care and outcomes. This company has quickly gained global recognition for its innovative solutions, which harness the power of genomics to transform healthcare.
Some significant milestones achieved by Sophia Genetics SA include securing a strategic partnership with Illumina, a global leader in DNA sequencing and array-based technologies. The company also expanded its genomic analysis platform to cover a wide range of genetic diseases, enabling more efficient and accurate diagnoses. Sophia Genetics SA has gained recognition by joining forces with renowned academic institutions and leading hospitals worldwide. Additionally, the company has received various prestigious awards, including being named a Global Cleantech prestigious 100 company. These achievements showcase Sophia Genetics SA's commitment to advancing genomic medicine and revolutionizing healthcare through innovative solutions and collaborations.
Sophia Genetics SA is primarily present in various countries and regions across the globe. Some of the key areas where the company has a significant presence include Europe, North America, Asia-Pacific, and the Middle East. With their advanced genomic data analysis solutions and services, Sophia Genetics SA has gained recognition and partnerships with renowned institutions, hospitals, and research centers in numerous countries. Their presence spans across multiple continents, making them a global leader in the field of genomics and personalized medicine.
Sophia Genetics SA represents values of innovation, collaboration, and integrity in the field of genetic testing and analysis. The company believes in harnessing the power of data and technology to revolutionize healthcare delivery. Sophia Genetics SA's corporate philosophy is centered around democratizing genomics, making it accessible and affordable for all. By providing advanced solutions for genomic data analysis, the company aims to empower healthcare professionals in making informed decisions and improving patient outcomes. Sophia Genetics SA's commitment to accuracy, transparency, and continuous research drives its mission to transform the future of personalized medicine.
Analysts currently set an average price target of 11.50 USD for the SOPHiA GENETICS stock (median: 11.50 USD), implying +42.3 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the SOPHiA GENETICS stock: 10 recommend buying, 1 holding and 0 selling. For 2026, analysts expect SOPHiA GENETICS to generate revenue of 95.26 M USD and earnings per share of -0.93 USD.
Converted at the current exchange rate, the SOPHiA GENETICS share trades at 7.26 EUR (8.26 USD).
The SOPHiA GENETICS share (SOPH) is listed on 2 stock exchanges, including: NASDAQ (SOPH), Frankfurt (90B.F).
Sophia Genetics SA is a Swiss company that specializes in providing advanced solutions for the analysis of genomic data. They work closely with leading hospitals and research institutions as part of their mission to improve healthcare. The business model of Sophia Genetics includes providing bioinformatics solutions to hospitals and clinics, using artificial intelligence and machine learning to improve clinical genomics and help doctors and researchers identify genetic anomalies and mutations faster and more accurately. Another important area of Sophia Genetics' business is collaboration with pharmaceutical companies in the development of personalized medicines. They collect and analyze data from patients with specific diseases to develop and test personalized treatment options. These partnerships also provide Sophia Genetics with access to large-scale studies and databases that provide more information about certain diseases. Sophia Genetics also offers a range of specialized products, including SOPHiA DDM, SOPHiA GENETICS Clinical Insights, SOPHiA AI Platform, and SOPHiA Solid Tumor Solution. SOPHiA DDM is a cloud-based platform that allows medical professionals and researchers to analyze genomic data and draw conclusions about diseases and treatment options. SOPHiA GENETICS Clinical Insights provides real-time interpretation support for the diagnosis and treatment of patients. SOPHiA AI Platform is an AI-based solution that helps interpret genomic data. SOPHiA Solid Tumor Solution is a diagnostic tool specialized in identifying genetic anomalies in tumor tissue samples. Sophia Genetics' technology is also applicable to a variety of industries, such as the agricultural industry. They collaborate with global biotechnology companies to develop new plant varieties and optimize agricultural processes. Over the years, Sophia Genetics has built numerous partnerships and collaborations with leading institutions and companies in the healthcare and bioinformatics industry. Their customers include hospitals, diagnostic laboratories, biorepositories, and pharmaceutical companies in Europe, North America, the Middle East, Africa, and Asia. In summary, the business model of Sophia Genetics SA is based on providing innovative bioinformatics solutions. They collaborate with leading institutions in the healthcare and bioinformatics industry and offer specialized products to improve the diagnosis and treatment of patients and develop personalized medicines. Their focus on collaboration with pharmaceutical companies and medical institutions, as well as the applicability of their technology to other industries, has made Sophia Genetics a key player in the journey towards personalized medicine.
The expected revenue of SOPHiA GENETICS is 95.26 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of SOPHiA GENETICS is -63.64 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of SOPHiA GENETICS is currently -8.86. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the SOPHiA GENETICS stock.
The price-to-sales ratio (P/S) of SOPHiA GENETICS is currently 5.92. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the SOPHiA GENETICS stock.
The Eulerpool Quality Score for SOPHiA GENETICS is 3/10.
The ISIN of SOPHiA GENETICS is CH1125843347. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of SOPHiA GENETICS is A3CVT8. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of SOPHiA GENETICS is SOPH. The ticker symbol is used to trade SOPHiA GENETICS shares on the stock exchange.
SOPHiA GENETICS paid dividends every year for the past 0 years.
SOPHiA GENETICS is assigned to the 'Health' sector.
The dividends of SOPHiA GENETICS are distributed in USD.
SOPHiA GENETICS stock
SOPHiA GENETICS Peer Group
SOPHiA GENETICS Ticker
SOPHiA GENETICS FIGI
All fundamentals and in-depth analysis of SOPHiA GENETICS
Our stock analysis for SOPHiA GENETICS stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SOPHiA GENETICS. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.